Blog Post | Focus on Regulation | 30 March 2017
The EU Court of Justice dismisses EMA’s appeals in interim measures and suspends the release of clinical study report to third parties
On March, 1st 2017, by Order of its Vice-President, the Court of Justice of the EU (“CJEU”) upheld the suspension of the release to third parties of a clinical study report concerning the medicinal product Translarna granted by the General Court in July 2016. On the same day, by Order of its Vice-President, the CJEU upheld also the suspension of the release of certain non-clinical study reports concerning the veterinary medicinal product Bravecto.
This blog focuses on the case concerning the medicinal product Translarna. The two Orders issued by the CJEU Vice-president on March 1st rely, however, on similar arguments in point of law.
To read more, click here.
Download PDF Back To Listing
